期刊文献+

沙利度胺联合化疗治疗多发性骨髓瘤的临床观察 被引量:7

下载PDF
导出
摘要 目的:观察沙利度胺(反应停)联合化疗治疗多发性骨髓瘤(MM)的临床疗效和不良反应。方法:13例MM患者分成2组,对照组用VAD方案化疗,治疗组在VAD方案上加用沙利度胺,治疗6个疗程,根据血清M蛋白、骨髓瘤细胞减少等指标判断疗效。结果:总有效率治疗组85.7%,对照组50.0%,两组间差异有显著性(P<0.05)。治疗组中便秘、腹胀和水肿增加,经对症处理后较快消失,其他不良反应与对照组相同。结论:沙利度胺联合VAD方案化疗治疗MM具有疗效明显增加,耐受性良好的优点。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2005年第8期755-756,共2页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献3

二级参考文献22

  • 1[1]Reist M,Carrupt PA,Francotte E,et al.Chiral inversion and hydrolysis of thalidomide:mechanisms and catalysis by bases and serum albumin,and chiral stability of teratogenic metabolites.Chem Res Toxicol,1998,11(12):1512~1528
  • 2[2]Teo SK,Sabourin PJ,O'Brein K,et al.Metabolism of thalidomide in human microsomes,cloned human cytochrome P-450 isozymes,and Hansen's disease patients.Biochem Mol Toxicol,2000,14(3):140~147
  • 3[3]Quilita R.Thalidomide in oncology:the peril and the promise.Cancer Control,1999,6(5):483~495
  • 4[4]D'Amato RJ,Loughnan MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci USA,1994,91:4082~4085
  • 5[5]Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide:focus on palliative care.Drugs,2000,60(2):273~292
  • 6[6]Argiles JM,Carbo N,Lopez SFJ,et al.Was tumour necrosis factor-alpha responsible for the fetal malformations.Med Hypotheses,1998,50(4):313~318
  • 7[7]Coleman M,Leonard JP,Nahum K,et al.Non-myelosuppre-ssive therapy with blt-d (Bianxin(r),low dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobulinemia and myeloma.Blood,2000,96(11):167a
  • 8[8]Haslett PA,Corral LG,Albert M,et al.Thalidomide costimulates primary human T lymphocytes,preferentially inducing.J Exp Med,1998,187(11):1885~1892
  • 9[9]Hideshima T,Chauhan D,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood,2000,96(9):2943~2950
  • 10[10]Geitz H,Handt S,Zwingenberger K,et al.Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.Immunopharmacology,1996,31(2-3):213~221

共引文献37

同被引文献49

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部